A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients
NCT ID: NCT01220115
Last Updated: 2019-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
498 participants
OBSERVATIONAL
2010-01-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No treatment
Patients aged 2 to less than 12
No interventions assigned to this group
No treatment patients aged 12 to less than 18
Patients aged 12 to less than 18
No interventions assigned to this group
No treatment Patients greater than 18 years
patients greater than 18 years
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 2 years old.
* Written informed consent by the patient or legal guardians, and pediatric assent where indicated.
Exclusion Criteria
* Patient or legal guardians unable or unwilling to give consent, or pediatric assent where indicated.
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hematology Oncology Services of Arkansas
Little Rock, Arkansas, United States
Children's Hospital Oakland (CHO)
Oakland, California, United States
Children's Hospital of Orange County Sickle Cell Disease Center
Orange, California, United States
Rady Children's Hopsital / UC San Diego University Hospital Sickle Cell Disease Center
San Diego, California, United States
Hematology Oncology, P.C.
Stamford, Connecticut, United States
Howard University
Washington D.C., District of Columbia, United States
Broward Oncology Associates, P.A.
Fort Lauderdale, Florida, United States
Miami Children's Hospital
Miami, Florida, United States
Innovative Medical Research
Miami, Florida, United States
M.D. Anderson Cancer Center Orlando
Orlando, Florida, United States
All Children's Hospital
St. Petersburg, Florida, United States
Central Tampa Hematology and Oncology Associates
Tampa, Florida, United States
St. Joseph Children's Hospital
Tampa, Florida, United States
University of Illinois at Chicago, Dept of Pediatrics
Chicago, Illinois, United States
Abington Hematology Oncology Associates, Inc
Oak Lawn, Illinois, United States
Tulane University School of Medicine
New Orleans, Louisiana, United States
LSU Department of Pediatrics Children's Hospital
New Orleans, Louisiana, United States
Johns Hopkins University Division of Hematology
Baltimore, Maryland, United States
Oncology-Hematology Associates, P.A.
Clinton, Maryland, United States
Children's Hospital Boston - Harvard
Boston, Massachusetts, United States
Boston Comprehensive Sickle Cell Center
Boston, Massachusetts, United States
West Michigan Cancer Center
Kalamazoo, Michigan, United States
University of Missouri Child Health, Division of Pediatric Hematology/Oncology
Columbia, Missouri, United States
Children's Mercy Hospital
Kansas City, Missouri, United States
Research Medical Center
Kansas City, Missouri, United States
Newark Beth Israel Medical Center
Newark, New Jersey, United States
Maimonides Medical Center
Brooklyn, New York, United States
New York Methodist Hospital Dept of Med/Sickle Cell Program
Brooklyn, New York, United States
Interfaith Medical Center-Comprehensive Sickle Cell Program
Brooklyn, New York, United States
Cohen Children's Medical Center of NY (CCMC)
New Hyde Park, New York, United States
Center for Children's Cancer & Blood Disorders
Syracuse, New York, United States
Presbyterian Hospital Pediatric Sickle Cell Program
Charlotte, North Carolina, United States
Ohio Region VI Sickle Cell Program
Akron, Ohio, United States
Cincinnati Children's Medical Center
Cincinnati, Ohio, United States
The Children's Medical Center of Dayton
Dayton, Ohio, United States
Medical University of SC-Pediatric Sickle Cell Center
Charleston, South Carolina, United States
M. Francisco Gonzalez, M.D., P.A.
Columbia, South Carolina, United States
Diggs-Kraus Sickle Cell Center
Memphis, Tennessee, United States
Meharry Comprehensive Sickle Cell Center
Nashville, Tennessee, United States
Sickle Cell Disease and Hemoglobinopathy Clinic Children's Hospital at Vanderbilt
Nashville, Tennessee, United States
Baylor College of Medicine-Texas Children's Hospital
Houston, Texas, United States
Peninsula Cancer Institute
Newport News, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CICL670AUS38
Identifier Type: -
Identifier Source: org_study_id